Soluble apoA-I can improve Vγ9Vδ2 T cell recognition of tumour cells, which overproduce IPP (that is, after ZA treatment), whereas low levels of circulating apoA-I in chronic inflammation are associated with a low activation state of Vγ9Vδ2 T cells11, 12, 13. The gene discussed is APOA1; the disease is neoplasm.